Extravascular use of drug-eluting beads: A promising approach in compartment-based tumor therapy

作     者：Simon Binder Andrew L Lewis J-Matthias Lhr Michael Keese 

作者机构：Faculty of Medicine MannheimUniversity of Heidelberg68167 MannheimGermany Biocompatibles UK Ltd.Department for Research and DevelopmentFarnham GU98QL SurreyUnited Kingdom Karolinska InstituteDepartment of Clinical ScienceIntervention and Technology17177 StockholmSweden Clinic for Vascular and Endovascular SurgeryUniversity Hospital Frankfurt60590 Frankfurt am MainGermany 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2013年第19卷第43期

页      面：7586-7593页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Compartment based therapy Intraperitoneal Drug-eluting beads Carcinomatosis Hyperthermic intraperitoneal chemotherapy Glioblastoma Pancreatic cancer CYP2B1 Ifosfamide 

摘      要：Intraperitoneal carcinomatosis(PC)may occur with several tumor *** prognosis of patients suffering from PC is usually *** treatment depends on the cancer entity and includes systemic chemotherapy,radiation therapy,hormonal therapy and surgical *** few patients may also benefit from hyperthermic intraperitoneal chemotherapy with a complete tumor *** therapies are often accompanied by severe systemic *** approach to reduce side effects is to target chemotherapeutic agents to the tumor with carrier *** experimental results have been achieved using drug-eluting beads(DEBs).A series of in vitro and in vitro experiments has been conducted to determine the suitability of their extravascular *** encapsulation devices were able to harbor CYP2B1producing cells and to shield them from the hosts immune system when injected *** this way ifosfamide-which is transformed into its active metabolites by CYP2B1-could be successfully targeted into pancreatic tumor *** DEBs can be used to target chemotherapeutics into the abdominal cavity for treatment of *** CYP2B1 producing cells are proven to be save for usage in man and if local toxic effects of chemotherapeutics can be controlled,DEBs will become promising tools in compartmentbased anticancer treatment.